Visilizumab

DB12053InvestigationalProtein Based Therapies

Visilizumab has been investigated for the treatment of Ulcerative Colitis.

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3 epsilon chain
Curator reviewed
Code names: HuM291

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

11Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Visilizumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.